Solid Tumors

Undefeated

I’m sure every cancer survivor feels this way, but my diagnosis, in 1997, of stage III germ cell testicular cancer couldn’t have come at a worse time in my life. I was nearing the end of a 60-city tour...

Symptom Management

Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors

“Immunotherapy has a completely different side-effect profile than chemotherapy, and that has caught physicians off guard,” noted Drew Pardoll, MD, PhD, in an article...

Lymphoma

BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma

A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses...


Advertisement
Lung Cancer

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration approved osimertinib for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors have epidermal growth factor receptor....

Colorectal Cancer

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients...


More Top Stories

Survivorship

Lynda M. Beaupin, MD, on Adhering to Follow-up Care: An Analysis

Yale Cancer Center Launches Immuno-Oncology Center

Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on Yale Cancer Center’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between Yale Cancer Center and the Department of...

Advertisement

Reciprocal Risks of Lymphoid Neoplasms and Cutaneous Melanoma

In a study reported in the Journal of the National Cancer Institute, Herr et al found that patients with specific types of primary lymphoid neoplasms were at increased risk of second primary cutaneous melanoma, with the reciprocal association also being observed. Occurrence of second primary...

Issues in Oncology
Cost of Care

Amy Kapczynski, JD, on Drug Development and the Cost of Researching and Treating Cancer

Hematologic Malignancies
Lymphoma

BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma

A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses with the Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) in patients with relapsed or refractory mantle cell lymphoma. ...

Conqueror in Action: Dr. Kurtz Takes on Lymphoma

WHAT IF people with blood cancer—and their doctors—could learn whether a treatment is working in real time?  Typically, it takes months to confirm whether cancer treatment is effective. For patients, this means months filled with worry and doubt: Am I getting better? What if the treatment isn’t...

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...

Prostate Cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Updated! ASCO Answers Guides to Breast Cancer, Colorectal Cancer, and Non–Small Cell Lung Cancer

FULLY UPDATED and now with 8th Edition American Joint Committee on Cancer (AJCC) staging information, ASCO Answers guides will help your patients get organized and learn more about their diagnosis, treatment options, side effects, support options, follow-up care, and more. Each guide includes...

Advertisement

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...